Invention Grant
US08541169B2 Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
有权
前列腺癌特异性的ERG基因表达变化和基于这些改变的检测和治疗方法
- Patent Title: Prostate cancer-specific alternations in ERG gene expression and detection and treatment methods based on those alterations
- Patent Title (中): 前列腺癌特异性的ERG基因表达变化和基于这些改变的检测和治疗方法
-
Application No.: US12444903Application Date: 2007-10-09
-
Publication No.: US08541169B2Publication Date: 2013-09-24
- Inventor: Shiv Srivastava , Albert Dobi , Taduru Sreenath , Gyorgy Petrovics , Chen Sun
- Applicant: Shiv Srivastava , Albert Dobi , Taduru Sreenath , Gyorgy Petrovics , Chen Sun
- Applicant Address: US MD Bethesda
- Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Current Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Current Assignee Address: US MD Bethesda
- Agency: MH2 Technology Law Group
- International Application: PCT/US2007/080826 WO 20071009
- International Announcement: WO2008/063769 WO 20080529
- Main IPC: C12Q1/68
- IPC: C12Q1/68
Abstract:
The disclosure describes alterations in ERG gene expression. ERG isoforms and promoter sequence of the ERG gene that are involved in, or associated with, prostate cancer are provided. The disclosure further provides therapeutic compositions and methods of detecting, diagnosing, prognosing, and treating prostate cancer, including biomarkers for detecting the expression of two or more of the following genes: PSA/KLK3, PMEPA1, NKX3.1, ODC1, AMD1, and ERG.
Public/Granted literature
Information query
